Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

Andrew J. Armstrong, MD
Published: Monday, Sep 25, 2017



Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Most of the approved drugs for patients with metastatic prostate cancer include immunotherapy, hormonal therapy, and chemotherapy. Precision medicine is the ability to use biomarkers for the optimal therapy, which makes treatment decisions easier for these patients, states Armstrong.

A blood test called the AR-V7 assay can help determine which patients will become resistant to enzalutamide (Xtandi) or abiraterone acetate (Zytiga), explains Armstrong.
 


Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Most of the approved drugs for patients with metastatic prostate cancer include immunotherapy, hormonal therapy, and chemotherapy. Precision medicine is the ability to use biomarkers for the optimal therapy, which makes treatment decisions easier for these patients, states Armstrong.

A blood test called the AR-V7 assay can help determine which patients will become resistant to enzalutamide (Xtandi) or abiraterone acetate (Zytiga), explains Armstrong.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x